EFFectiveness of once-weekly insulin ICodec versus once-daily basal Insulin analogues in an insulin-naïve type 2 diabEtes population in real-world cliNical pracTice- The EFFICIENT pragmatic study
This research study, called EFFICIENT, focuses on people in the UK with type 2 diabetes who are starting insulin treatment for the first time. The main goal is to compare a new type of insulin, called Icodec, which is taken once a week, with other insulins that people usually take daily. Researchers want to understand how effective these insulins are at controlling blood sugar levels over time. They also want to see how easy and comfortable people find each treatment to use in their daily lives. By looking at these real-world experiences, the study hopes to find out which insulin approach might be best for patients. It's about finding treatments that not only work well but also fit into people's lives more easily.
At a glance
What is this study about?
Imagine you have type 2 diabetes and your doctor thinks it's time to start insulin to help control your blood sugar. There are different types of insulin, and some you take every day. Now, there's a newer kind of insulin being looked at called Icodec, which you only take once a week. This study, called EFFICIENT, is designed to see how well this once-a-week insulin works compared to the daily insulins that are already commonly used.
Researchers are interested in how much your blood sugar levels (measured by something called HbA1c, which gives an average over a few months) change after about a year of treatment. They also want to know how you feel about your treatment – how satisfied you are, how easy it is to stick to your treatment plan, and if it feels like a big burden. This information is really important because it helps doctors understand not just which medicines work, but also which ones make life easier for patients.
This study is happening in real-world clinics and practices, which means it reflects how things are done day-to-day for people with type 2 diabetes starting insulin. By comparing a once-weekly insulin with daily ones, the study aims to give doctors and patients more clear information when deciding on the best insulin treatment plan. It’s all about finding ways to help people manage their diabetes effectively and comfortably.
Key takeaways
- Compares a new once-weekly insulin with daily insulins.
- For people with type 2 diabetes just starting insulin.
- Aims to improve diabetes management and ease of use.
- Study lasts for approximately one year.
- Monitors blood sugar control and patient experience.
Who may be eligible?
Anyone aged 18 or older can be considered for this study if they have type 2 diabetes and are just about to start taking insulin for the first time. This study is for people who haven't used insulin before for their diabetes.
Both men and women are welcome to participate. The important thing is that your doctor has decided that starting insulin treatment is the next step for you.
There might be other health conditions or medications that would mean you couldn't join, but the initial check is mainly about your age, having type 2 diabetes, and being new to insulin.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have type 2 diabetes?
- Has your doctor recently recommended starting insulin treatment?
- Have you never taken insulin for your diabetes before?
What does participation involve?
If you join this study, you'll be part of a group comparing different insulin treatments for type 2 diabetes. You will receive either the new once-weekly insulin (Icodec) or one of the daily insulins that doctors commonly prescribe. All insulins involved are already approved medicines. You'll continue to see your doctor regularly, just as you would for your usual diabetes care.
The study will follow your progress for about a year (52 weeks). During this time, your blood sugar levels will be checked, likely through blood tests (HbA1c). You'll also be asked to fill out questionnaires about how you feel about your treatment, how satisfied you are with it, and how easy or difficult you find it to manage. These questionnaires help researchers understand your experience with the medication.
There won't be extra visits beyond what your doctor would normally recommend for monitoring your diabetes when starting insulin. You'll use the insulin as directed by your doctor, either once a week or once a day, depending on which one you're on. The total duration of active participation in the study is 52 weeks.
Potential risks and benefits
Locations (2)
- —UnverifiedGermany
- —UnverifiedItaly
Common questions
What is the main purpose of this study?
The study aims to compare a new once-weekly insulin with common daily insulins for people with type 2 diabetes who are starting insulin treatment.
What is HbA1c?
HbA1c is a blood test that shows your average blood sugar levels over the past 2-3 months. It's a key way to monitor diabetes control.
Will I have to pay to be part of the study?
No, you will not have to pay for the study treatments or assessments. Your participation is voluntary and free of charge.
What kind of questions will I be asked?
You'll be asked about how you feel about your diabetes treatment, how easy it is to use, and your general satisfaction with your medication.
How long will I be in the study?
If you join, you will be part of the study for about one year (52 weeks).
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.